A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

被引：0
|
作者：
Weiss, G. [1 ]
Donehower, R. [2 ]
Westin, E. [3 ]
Bence, A. [4 ]
Hynes, S. [5 ]
Hurt, K. [6 ]
机构：
[1] TGEN Clin Res, Canc & Cell Biol Div, Scottsdale, AZ USA
[2] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA
[3] Eli Lilly & Co, Med Oncol Exploratory Preclin, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Program Phase, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Clin Oncol, Indianapolis, IN 46285 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72223-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [31] A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
    D. S. Hong
    R. Kurzrock
    A. Naing
    J. J. Wheler
    G. S. Falchook
    J. S. Schiffman
    N. Faulkner
    M. J. Pilat
    J. O’Brien
    P. LoRusso
    Investigational New Drugs, 2014, 32 : 436 - 444
  • [32] A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
    Hong, D. S.
    Kurzrock, R.
    Naing, A.
    Wheler, J. J.
    Falchook, G. S.
    Schiffman, J. S.
    Faulkner, N.
    Pilat, M. J.
    O'Brien, J.
    LoRusso, P.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 436 - 444
  • [33] Phase 1 dose-escalation study of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma: preliminary results of tolerability and effect on immunologic biomarkers
    McArthur, G. A.
    Cebon, J.
    Skrumsager, B. K.
    Skak, K.
    Davis, I. D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 148 - 148
  • [34] Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer
    N Hanna
    P Ohana
    F M Konikoff
    G Leichtmann
    A Hubert
    L Appelbaum
    Y Kopelman
    A Czerniak
    A Hochberg
    Cancer Gene Therapy, 2012, 19 : 374 - 381
  • [35] Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer
    Hanna, N.
    Ohana, P.
    Konikoff, F. M.
    Leichtmann, G.
    Hubert, A.
    Appelbaum, L.
    Kopelman, Y.
    Czerniak, A.
    Hochberg, A.
    CANCER GENE THERAPY, 2012, 19 (06) : 374 - 381
  • [36] Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study
    Hong, Ruoxi
    Xia, Wen
    Wang, Liye
    Lee, Kaping
    Lu, Qianyi
    Jiang, Kuikui
    Li, Shengfeng
    Yu, Jinquan
    Wei, Jin
    Tang, Weijia
    Zhou, Danyang
    An, Xin
    Huang, Jiajia
    Xue, Cong
    Bi, Xiwen
    Shi, Yanxia
    Yuan, Zhongyu
    Xu, Fei
    Wang, Shusen
    CANCER COMMUNICATIONS, 2021, 41 (02) : 171 - 182
  • [37] A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors
    Le Tourneau, Christophe
    Su, Wu-Chou
    Chung, Ki
    LoRusso, Patricia
    Lin, Chia-Chi
    Barlesi, Fabrice
    Shiah, Her-Shyong
    Angevin, Eric
    Spira, Alexander
    Patnaik, Amita
    Powderly, John
    Colevas, Dimitrios
    Chew, Helen
    Patel, Maulik
    Lambert, Stacie
    Li, Yan
    Da Costa, Daniel
    Blaney, Martha
    McDevitt, Michael
    Cassier, Philippe
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [38] A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)
    Demidov, Lev
    Kharkevich, Galina
    Petenko, Natalia
    Moiseenko, Vladimir
    Protsenko, Svetlana
    Semiglazova, Tatiana
    Zimina, Anastasia
    Kovalenko, Nadezhda
    Fadeeva, Natalia
    Kirtbaya, Dmitry
    Belogortsev, Igor
    Tantsyrev, Denis
    Odintsova, Svetlana
    Nesterova, Alfia
    Vorontsova, Karina
    Makarycheva, Yulia
    Linkova, Yulia
    Zinkina-Orikhan, Arina
    Siliutina, Anna
    Sorokina, Irina
    Liaptseva, Daria
    Chistyakov, Vladimir
    Lutsky, Anton
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Phase 1 Dose-Escalation Study of the Investigational HER2/EGFR Inhibitor TAK-285 in Patients with Advanced Cancer
    LoRusso, P.
    Chiorean, E. G.
    Heath, E.
    Weise, A.
    Foley, M.
    Olivo, Y. S.
    Chi, X.
    Corvez, M.
    Venkatakrishnan, K.
    Sausville, E.
    CANCER RESEARCH, 2010, 70
  • [40] A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors.
    Heath, E. I.
    Alousi, A.
    Eder, J. P.
    Valdivieso, M.
    Vasist, L. S.
    Appleman, L.
    Bhargava, P.
    Colevas, A. D.
    Lorusso, P. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 85S - 85S
12345